CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade Estadual Paulista (UNESP). Campus de Araraquara. Faculdade de Ciências Farmacêuticas (FCFAR) (Institutional affiliation for the last research proposal) Birthplace: Brazil
Associate Professor at the School of Pharmaceutical Sciences (FCF), UNESP-Araraquara. Bachelor degree in Pharmacy (2004) at School of Pharmaceutical Science (FCF-UNESP), Master's (2006) and Ph.D. (2009) in Pharmaceutical Sciences. Post-doctorate (2016) in Medicinal Chemistry at the University of Minnesota (United States). He is a research fellow in Technological Development and Innovative Extension level 2. Experience in drug design innovation, mainly using processes of optimization and molecular modification. He is one of the coordinators of the Research and Development of New Drugs Laboratory (Lapdesf - UNESP). He coordinates ongoing research projects financed by development agencies such as FAPESP and CNPq. He collaborated on research projects with national and multinational pharmaceutical products (GlaxoSmithKline). It has patents granted in the USA, the European Community and China. It has more than 21 patents deposited and granted, some of which have been studied for the transfer of technology for pharmaceutical products.He is an advisor at the master's and doctoral level in Graduate Excellence Programs (Graduate Program in Chemistry IQ UNESP - CAPES 7 and Graduate Program in Pharmaceutical Sciences-FCF-UNESP - CAPES 6). (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Although advances have been made in recent years for the treatment of tuberculosis (TB), huge challenges such as the emergence of resistant strains become distant the goals to achieve the eliminating the disease in the near future. According to the World Health Organization (WHO), in 2018 about 10 million new cases were diagnosed and 1.2 million deaths occurred. Among the new cases, 484,0…
A few years ago the World Health Organization (WHO) established as one of the its goals the eradication of tuberculosis by the year 2015. Far from this aim, we reached the year 2016 within 10.4 million new cases of tuberculosis (TB) and 1.3 million deaths worldwide. The emergence of resistant strains is one of the factors that justify the difficulty of reaching the goal proposed by WHO. T…
Sickle cell disease (SCD) is one of the most prevalent chronic hereditary hemoglobinopathies worldwide. Currently, the only drug available for its treatment is hydroxyurea, responsible among other actions, to increase the levels of fetal hemoglobin (HbF). Gamma-globin gene regulation is complex and involves various proteins and enzymes, such as histone deacetylase (HDAC). HADC inhibitors…
(Only some records are available in English at this moment)
Although the treatment of tuberculosis (TB) has been made advances in recent years, it can be noted huge challenges such as the emergence of resistant strains become difficult the goals to achieve the eliminating the disease soon. According to the World Health Organization (WHO), in 2018 about 10 million new cases were diagnosed and around 1.2 million deaths occurred. Among the new cases,…
Sickle Cell Anemia (SCA) is a genetic hemoglobinopathy characterized by chronic hemolytic anemia, pain and damage to various organs, leading to wide clinical variability and decreased life expectancy. Increased levels of fetal hemoglobin (HbF) is a validated approach to treatment. Among the strategies described to elevate HbF levels, the inhibition of the enzymes Histone Deacetylase (HDAC…
Sickle Cell Anemia (SCA) is the most prevalent genetic disease in world. The lack of new drugs and the low life expectancy are the cruel aspects of the disease. Nowadays, the therapeutic resource include hydroxyurea (HU) and supplementation with glutamine. In vivo, HU is bioconverted in nitric oxide which results in beneficial effects, being the increase in fetal hemoglobin production one…
According to the World Health Organization, leishmaniasis are neglected diseases that affects 12 million people worldwide and puts at risk 350 million people. The current therapy has a number of limitations and drawbacks justifying the search for new drugs more effective and safe. Recently, studies have shown that N-oxides compounds are active against amastigote forms of Leishmania amazon…
(Only some records are available in English at this moment)
Sickle Cell Disease (SCD) is the most prevalent hematological genetic disease worldwide. In Brazil, it afflicts, annually, about 3,500 newborns and approximately 300,000 cases of sickle trait carriers have been reported. Vaso-occlusive crises, intense pain and organ infarcts are among the main symptoms and complications of SCD, leading to high rates of morbidity and mortality. Currently, …
Mycobacterium tuberculosis (MTB), the main agent that causes tuberculosis (TB), is responsible for the annual death of 1.5 million people worldwide. Currently, one of the biggest global concerns is the increasing number of cases of multidrug-resistant (MDR-TB) and extensively drug resistant (XDR-TB) strains due to the high mortality rate, difficulty in treatment and the high costs involve…
Sickle Cell Disease (SCD) is one of the most prevalent inherited blood disorders. This genetic disease is characterized by a single substitution of aminoacids (glutamic acid to valine) at the ²-globin chain leading to hemoglobin polymerization at low oxygen environment. The sickle-shaped cells have exhibited high adherence to the vascular endothelium and contribute to inflammatory panel…
The dyslipidemia is a disease caused by increased levels of lipids levels into bloodstream widely prevalent worldwide. According to Brazilian Cardiology Society the disease is classified as Hypercolesterolemia (high levels of Low Density Lipoprotein-LDL), Hypertriglyceridemia (high levels of triglycerides-TG), Mixed Hyperlipidemia (high levels of both LDL and TG) and Low High Density Lipo…
(Only some records are available in English at this moment)
| 1 / 1 | Ongoing research grants |
| 7 / 6 | Completed research grants |
| 1 / 1 | Ongoing scholarships in Brazil |
| 16 / 16 | Completed scholarships in Brazil |
| 1 / 1 | Ongoing scholarships abroad |
| 5 / 5 | Completed scholarships abroad |
| 31 / 30 | All research grants and scholarships |
| Associated processes | |